Top

Published in:

Open Access 01-10-2005 | Research article

Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats

Authors: Reza Hakkak, Andy W Holley, Stewart L MacLeod, Pippa M Simpson, George J Fuchs, Chan Hee Jo, Thomas Kieber-Emmons, Soheila Korourian

Published in: Breast Cancer Research | Issue 5/2005

Abstract

Introduction

High body mass index has been associated with increased risk for various cancers, including breast cancer. Here we describe studies using 7,12-dimethylbenz(a)anthracene (DMBA) to investigate the role of obesity in DMBA-induced mammary tumor susceptibility in the female Zucker rat (fa/fa), which is the most widely used rat model of genetic obesity.

Method

Fifty-day-old female obese (n = 25) and lean (n = 28) Zucker rats were orally gavaged with 65 mg/kg DMBA. Rats were weighed and palpated twice weekly for detection of mammary tumors. Rats were killed 139 days after DMBA treatment.

Results

The first mammary tumor was detected in the obese group at 49 days after DMBA treatment, as compared with 86 days in the lean group (P < 0.001). The median tumor-free time was significantly lower in the obese group (P < 0.001). Using the days after DMBA treatment at which 25% of the rats had developed mammary tumors as the marker of tumor latency, the obese group had a significantly shorter latency period (66 days) than did the lean group (118 days). At the end of the study, obese rats had developed a significantly (P < 0.001) greater mammary tumor incidence (68% versus 32%) compared with the lean group. The tumor histology of the mammary tumors revealed that obesity was associated with a significant (P < 0.05) increase in the number of rats with at least one invasive ductal and lobular carcinoma compared with lean rats.

Conclusion

Our results indicate that obesity increases the susceptibility of female Zucker rats to DMBA-induced mammary tumors, further supporting the hypothesis that obesity and some of its mediators play a significant role in carcinogenesis.

Available only for authorised users

National Center for Health Statistics: National Health and Nutrition Examination Survey. [http://www.cdc.gov/nchs/nhanes.htm]

Anonymous: NHLBI Obesity Education Initiative Expert Panel. Obes Res. 1998, 6: 51S-CrossRef

Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003, 289: 76-79. 10.1001/jama.289.1.76.CrossRefPubMed

Cleary MP, Maihle NJ: The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997, 216: 28-43.CrossRefPubMed

Willett WC: Fat, energy and breast cancer. J Nutr. 1997, 127: 921S-923S.PubMed

Galanis DJ, Kolonel LN, Lee J, Le Marchand L: Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control. 1998, 9: 217-224. 10.1023/A:1008842613331.CrossRefPubMed

Ballard-Barbash R, Swanson CA: Body weight: estimation of risk for breast and endometrial cancers. Am J Clin Nutr. 1996, 63: 437S-441S.PubMed

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348: 1625-1638. 10.1056/NEJMoa021423.CrossRefPubMed

Waxler SH, Tabar P, Melcher LR: Obesity and the time of appearance of spontaneous mammary carcinoma in C3H mice. Cancer Res. 1953, 13: 276-278.PubMed

10.

Waxler S: Obesity and cancer susceptibility in mice. Am J Clin Nutr. 1960, 8: 760-766.

11.

Haseman JK, Bourbina J, Eustis SL: Effect of individual housing and other experimental design factors on tumor incidence in B6C3F1 mice. Fundam Appl Toxicol. 1994, 23: 44-52. 10.1006/faat.1994.1077.CrossRefPubMed

12.

Wolff GL, Kodell RL, Cameron AM, Medina D: Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c X VY) F1 hybrid mice. J Toxicol Environ Health. 1982, 10: 131-142.CrossRefPubMed

13.

Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, et al: Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995, 83: 1263-1271. 10.1016/0092-8674(95)90151-5.CrossRefPubMed

14.

Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996, 271: 994-996.CrossRefPubMed

15.

Zucker L, Zucker TF: Fatty, a new mutation in the rat. J Heredity. 1961, 52: 275-278.

16.

Zucker TF, Zucker LM: Fat accretion and growth in the rat. J Nutr. 1963, 80: 6-19.PubMed

17.

Zucker LM: Fat mobilization in vitro and in vivo in the genetically obese Zucker rat 'fatty'. J Lipid Res. 1972, 13: 234-243.PubMed

18.

Bray GA, York DA, Fisler JS: Experimental obesity: a homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system. Vitam Horm. 1989, 45: 1-125.CrossRefPubMed

19.

Bray GA: The Zucker-fatty rat: a review. Fed Proc. 1977, 36: 148-153.PubMed

20.

Lee WM, Lu S, Medline A, Archer MC: Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N-methyl-N-nitrosourea. Cancer Lett. 2001, 162: 155-160. 10.1016/S0304-3835(00)00635-2.CrossRefPubMed

21.

Hakkak R, Korourian S, Shelnutt SR, Lensing S, Ronis MJ, Badger TM: Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Cancer Epidemiol Biomarkers Prev. 2000, 9: 113-117.PubMed

22.

Hakkak R, Kourourian S, Fletcher T, Hale J, Fergusonn M, Ronis M, Badger T: The effects of rice protein isolate on DMBA-induced mammary tumors in rats. Proc Am Assoc Cancer Res. 2002, 48: 823-

23.

Altman DG: Practical Statistics for Medical Research. 1991, London: Chapman and Hall

24.

Cox DR, Oakes D: Analysis of Survival Data. 1984, London: Chapman and Hall

25.

Gross AJ, Clark VA: Survival Distribution: Reliability Applications in Biomedical Sciences. 1975, New York: Wiley

26.

Bhattacharyya GK, Johnson RA: Statistical Concepts and Methods. 1977, New York: Wiley

27.

Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952, 47: 583-621.CrossRef

28.

Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D: Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med. 1991, 196: 381-384.CrossRefPubMed

29.

Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin: a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst. 2002, 94: 1704-1711.CrossRefPubMed

30.

Klurfeld DM, Welch CB, Lloyd LM, Kritchevsky D: Inhibition of DMBA-induced mammary tumorigenesis by caloric restriction in rats fed high-fat diets. Int J Cancer. 1989, 43: 922-925.CrossRefPubMed

31.

Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW: Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res. 1989, 49: 4130-4134.PubMed

32.

Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, et al: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer. 2004, 111: 762-771. 10.1002/ijc.20315.CrossRefPubMed

33.

van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, et al: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000, 152: 514-527. 10.1093/aje/152.6.514.CrossRefPubMed

34.

Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, et al: Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002, 13: 741-751. 10.1023/A:1020239211145.CrossRefPubMed

35.

Rowlands JC, He L, Hakkak R, Ronis MJ, Badger TM: Soy and whey proteins downregulate DMBA-induced liver and mammary gland CYP1 expression in female rats. J Nutr. 2001, 131: 3281-3287.PubMed

36.

Russo J, Russo IH: Experimentally induced mammary tumors in rats. Breast Cancer Res Treat. 1996, 39: 7-20.CrossRefPubMed

37.

Russo IH, Russo J: Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect. 1996, 104: 938-967.CrossRefPubMedPubMedCentral

38.

Weber RV, Stein DE, Scholes J, Kral JG: Obesity potentiates AOM-induced colon cancer. Dig Dis Sci. 2000, 45: 890-895. 10.1023/A:1005560621722.CrossRefPubMed

39.

White BD, Martin RJ: Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med. 1997, 214: 222-232.CrossRefPubMed

40.

Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, Olsson T: Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004, 86: 191-196. 10.1023/B:BREA.0000036782.11945.d7.CrossRefPubMed

41.

Enger SM, Greif JM, Polikoff J, Press M: Body weight correlates with mortality in early-stage breast cancer. Arch Surg. 2004, 139: 954-960. 10.1001/archsurg.139.9.954.CrossRefPubMed

42.

Li D, Wang M, Dhingra K, Hittelman WN: Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res. 1996, 56: 287-293.PubMed

43.

Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP: The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis. 2000, 21: 1281-1289. 10.1093/carcin/21.7.1281.CrossRefPubMed

44.

Trayhurn P, Wood IS: Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004, 92: 347-355. 10.1079/BJN20041213.CrossRefPubMed

Title: Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats
Authors: Reza Hakkak
Andy W Holley
Stewart L MacLeod
Pippa M Simpson
George J Fuchs
Chan Hee Jo
Thomas Kieber-Emmons
Soheila Korourian
Publication date: 01-10-2005
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1263

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2005

A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT)

How many genes are needed for early detection of breast cancer, based on gene expression patterns in peripheral blood cells?

High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer